Join to view full profile
9500 Euclid AveCleveland, OH 44195
Phone+1 216-444-2200
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 3 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Anthony Fernandez, MD is a board certified dermatologist in Cleveland, Ohio. He is currently licensed to practice medicine in Ohio and Florida.
Education & Training
Cleveland Clinic FoundationFellowship, Dermatopathology, 2011
University of Miami/Jackson Health SystemResidency, Dermatology, 2006 - 2009
Loyola University Medical CenterInternship, Internal Medicine, 2005 - 2006
University of Illinois College of MedicineClass of 2005
Certifications & Licensure
FL State Medical License 2023 - 2027
OH State Medical License 2009 - 2027
American Board of Dermatology Dermatology- American Board of Dermatology Dermatopathology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
Publications & Presentations
PubMed
- Histopathologic Features of Acral Skin Biopsies in Dermatomyositis Patients and Comparison to Histopathologic Features in Non-Acral Biopsies.Lydia Cassard, Firdous Ali, Elizabeth M Flatley, Anthony Patrick Fernandez
Journal of Cutaneous Pathology. 2025-04-01 - 35 citationsIdiopathic inflammatory myopathies related lung disease in adults.Sameep Sehgal, Aditi Patel, Soumya Chatterjee, Anthony P Fernandez, Carol Farver
The Lancet. Respiratory Medicine. 2025-03-01 - 27 citationsEfficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, p...David Fiorentino, Aaron R Mangold, Victoria P Werth, Lisa Christopher-Stine, Alisa Femia
Lancet. 2025-01-11
Authored Content
- Creation and Validation of Classification Criteria for Discoid Lupus ErythematosusJune 2020
- Creation and Validation of Classification Criteria for Discoid Lupus ErythematosusJune 2020
- Creation and Validation of Classification Criteria for Discoid Lupus ErythematosusJune 2020
Press Mentions
Dermatologists, Rheumatologists, and Patients Debate the Role of GLP-1 Drugs in Psoriasis and Psoriatic ArthritisJuly 22nd, 2025- Diabetes Technology: Part TwoMay 21st, 2025
- Diabetes Technology: Part OneApril 21st, 2025